Collaboration involves the marketing and distribution of PreHevbri across Europe
News
Neuroplast receives medicinal product designation for Neuro-Cells
Designation paves way for wider applications for several neurodegenerative diseases
UCB reveals new Bimzelx ‘complete skin clearance’ data
Positive data represents a boost for patients with moderate to severe plaque psoriasis
Brainomix and Bridge Biotherapeutics enter artificial intelligence partnership
Link up will utilise Brainomix’s AI software for the assessment of idiopathic pulmonary fibrosis
PhoreMost in drug target discovery collaboration with Roche
PhoreMost will use Siteseeker platform to identify novel targets for Roche’s discovery programmes
BioInnovation Institute reveals new cohort entering Venture Lab programme
Group consists of nine ventures plus corporate-sponsored innovation projects from Novo Nordisk
New PM will ‘inherit an NHS in its most challenging state for decades’
Warning comes from NHS leaders as new Prime Minister prepares to move into Number 10
Sanofi and Regeneron’s Dupixent shows consistent safety profile
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
First patient enrolled in Modus’ sevuparin trial
Research is evaluating the therapy among paediatric patients with severe malaria
Green light for cancer drugs developed by AI specialist Owkin
AI company has its breast cancer and colorectal therapies approved for use in Europe
Avacta announces clinical study of AVA6000
Pro-doxorubicin will advance to the fourth dose following a positive review of safety and tolerability
Manus Bio receives additional funding to combat malaria
Fourth award from the Bill & Melinda Gates Foundation will support artemisinin research
Kaiku Health enters wider partnership with Novartis
Following a successful collaboration, the companies will now partner to focus on precision medicine
Psyomics links up with Hertfordshire Partnership University NHS Foundation Trust
Hertfordshire Trust to invest in mental health care with wide-ranging digital assessment platform
European Commission approves pharma trio’s Ranivisio
Therapy is a biosimilar of Lucentis which treats several serious retinal diseases across the European Union
